A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

Inclusion Criteria Concurrent Medication: Allowed: * Short-term nonsteroidal anti-inflammatory therapy. Patients must have: * HIV seropositivity. * CD4 count \>= 500 cells/mm3. * Successful establishment of EBV-transformed B-cell lines at study entry. * Consent of parent or guardian if \< 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Suspected or known allergies to any vaccine components. * Medical contraindication. * Problem with compliance. Concurrent Medication: Excluded: * Antiretroviral therapy (e.g., AZT, ddI, or ddC). * Agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin). * Parenteral therapies (including SC allergy sensitization). * Other investigational HIV drugs or therapies. Prior Medication: Excluded: * Any prior vaccinations against HIV. * Antiretroviral therapy (e.g., AZT, ddI, or ddC) within the past 6 months. * Agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin) within the past 3 months. * Parenteral therapies (including SC allergy sensitization) within the past 3 months. * Other investigational HIV drugs or therapies within the past 3 months.